The unique antigen-presenting capabilities of dendritic cells (DCs) make them an attractive means with which to initiate an antitumor immune response. Using DCs transduced with tumor antigens for immunotherapy has several theoretical advantages over peptide-pulsed DCs including the possibility that transduced DCs are capable of presenting epitopes on both class I and class II MHC molecules. To test this theory, we inserted the human tumor antigen gp100 into mouse DCs transgenic for HLA-DRbeta1*0401 using either adenoviral vector or a VSV-G pseudotyped retroviral vector. DCs transduced with tumor antigen were able to be recognized by both a murine CD8(+) T-cell clone and a murine CD4(+) T-cell line in a cytokine release assay, thereby demonstrating presentation of both MHC class I and class II gp100 epitopes. This study describes the simultaneous presentation of a tumor-associated antigen to both CD4(+) and CD8(+) T cells and lends support to the use of gene-modified DCs as a means to initiate both CD4(+) and CD8(+) antitumor responses.

中文翻译：

---

逆转录病毒和腺病毒转导的树突状细胞中肿瘤抗原的MHC I类和II类呈递。

树突状细胞（DC）独特的抗原呈递能力使其成为引发抗肿瘤免疫应答的有吸引力的手段。使用经肿瘤抗原转导的DC进行免疫治疗具有优于肽脉冲DC的几个理论优势，包括转导的DC能够在I类和II类MHC分子上呈递表位的可能性。为了验证该理论，我们使用腺病毒载体或VSV-G假型逆转录病毒载体将人肿瘤抗原gp100插入了针对HLA-DRbeta1 * 0401转基因的小鼠DC中。在细胞因子释放试验中，鼠CD8（+）T细胞克隆和鼠CD4（+）T细胞系都能够识别用肿瘤抗原转导的DC，从而证明了MHC I类和II类均呈递gp100表位。